ULIH.F Stock Overview
The United Laboratories International Holdings Limited, an investment holding company, engages in the research and development, manufacture, distribution, and sale of pharmaceutical products.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
The United Laboratories International Holdings Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.89 |
| 52 Week High | HK$0.89 |
| 52 Week Low | HK$0.83 |
| Beta | 0.026 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | 20.73% |
| 5 Year Change | n/a |
| Change since IPO | -28.54% |
Recent News & Updates
Recent updates
Shareholder Returns
| ULIH.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | -1.5% | -3.2% |
| 1Y | n/a | 9.7% | 19.3% |
Return vs Industry: Insufficient data to determine how ULIH.F performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how ULIH.F performed against the US Market.
Price Volatility
| ULIH.F volatility | |
|---|---|
| ULIH.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ULIH.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ULIH.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 14,000 | n/a | www.tul.com.cn |
The United Laboratories International Holdings Limited, an investment holding company, engages in the research and development, manufacture, distribution, and sale of pharmaceutical products. It operates through three segments: Bulk Medicine, Intermediate Products, and Finished Products. The company offers oral antibiotics, antimicrobials for injection, anti-cold products, cough medicines, ophthalmic drugs, antiviral drugs, anti-hepatitis B drugs, diabetes drugs, skin drugs for external use, cardiovascular and cerebrovascular drugs, amoxicillin products, nervous system drugs, vitamins, veterinary drugs, and vacant gelatin capsules, as well as active pharmaceutical ingredients and intermediate products.
The United Laboratories International Holdings Limited Fundamentals Summary
| ULIH.F fundamental statistics | |
|---|---|
| Market cap | US$1.98b |
| Earnings (TTM) | US$310.63m |
| Revenue (TTM) | US$1.81b |
6.6x
P/E Ratio1.1x
P/S RatioIs ULIH.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ULIH.F income statement (TTM) | |
|---|---|
| Revenue | CN¥13.06b |
| Cost of Revenue | CN¥7.13b |
| Gross Profit | CN¥5.93b |
| Other Expenses | CN¥3.69b |
| Earnings | CN¥2.24b |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.23 |
| Gross Margin | 45.40% |
| Net Profit Margin | 17.12% |
| Debt/Equity Ratio | 13.2% |
How did ULIH.F perform over the long term?
See historical performance and comparison